Switch theme
Sign up to access all valuation multiples
BerGenBio ASA is a clinical-stage biopharmaceutical company developing drugs for aggressive diseases, including drug resistant and metastatic cancers and respiratory disease. Its product, bemcentinib (BGB324), is a selective, potent, oral small molecule AXL inhibitor that has been tested in a various indications including NSCLC, AML and severe respiratory infections.
2007
13
LTM Revenue $0.1M
LTM EBITDA -$14.7M
-$6.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BerGenBio has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of -$14.7M.
In the most recent fiscal year, BerGenBio achieved revenue of $0.1M and an EBITDA of -$13.6M.
BerGenBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BerGenBio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$14.7M | XXX | -$13.6M | XXX | XXX | XXX |
| EBITDA Margin | -28720% | XXX | -16371% | XXX | XXX | XXX |
| EBIT | -$14.8M | XXX | -$14.8M | XXX | XXX | XXX |
| EBIT Margin | -28806% | XXX | -17834% | XXX | XXX | XXX |
| Net Profit | -$13.6M | XXX | -$13.6M | XXX | XXX | XXX |
| Net Margin | -26530% | XXX | -16425% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BerGenBio's stock price is NOK 2 (or $0).
BerGenBio has current market cap of NOK 71.6M (or $7.0M), and EV of -NOK 66.9M (or -$6.5M).
See BerGenBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$6.5M | $7.0M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BerGenBio has market cap of $7.0M and EV of -$6.5M.
BerGenBio's trades at -78.8x EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate BerGenBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BerGenBio has a P/E ratio of -0.5x.
See valuation multiples for BerGenBio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.0M | XXX | $7.0M | XXX | XXX | XXX |
| EV (current) | -$6.5M | XXX | -$6.5M | XXX | XXX | XXX |
| EV/Revenue | -127.3x | XXX | -78.8x | XXX | XXX | XXX |
| EV/EBITDA | 0.4x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/Gross Profit | -127.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBerGenBio's revenue per employee in the last FY averaged $6K, while opex per employee averaged $1.1M for the same period.
BerGenBio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BerGenBio's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BerGenBio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -28720% | XXX | -16371% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $6K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10341% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17934% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BerGenBio acquired XXX companies to date.
Last acquisition by BerGenBio was XXXXXXXX, XXXXX XXXXX XXXXXX . BerGenBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BerGenBio founded? | BerGenBio was founded in 2007. |
| Where is BerGenBio headquartered? | BerGenBio is headquartered in Norway. |
| How many employees does BerGenBio have? | As of today, BerGenBio has 13 employees. |
| Who is the CEO of BerGenBio? | BerGenBio's CEO is Mr. Martin Olin. |
| Is BerGenBio publicy listed? | Yes, BerGenBio is a public company listed on OSL. |
| What is the stock symbol of BerGenBio? | BerGenBio trades under BGBIO ticker. |
| When did BerGenBio go public? | BerGenBio went public in 2017. |
| Who are competitors of BerGenBio? | Similar companies to BerGenBio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BerGenBio? | BerGenBio's current market cap is $7.0M |
| What is the current revenue of BerGenBio? | BerGenBio's last 12 months revenue is $0.1M. |
| What is the current EV/Revenue multiple of BerGenBio? | Current revenue multiple of BerGenBio is -127.3x. |
| Is BerGenBio profitable? | Yes, BerGenBio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BerGenBio? | BerGenBio's last 12 months EBITDA is -$14.7M. |
| What is BerGenBio's EBITDA margin? | BerGenBio's last 12 months EBITDA margin is -28720%. |
| What is the current EV/EBITDA multiple of BerGenBio? | Current EBITDA multiple of BerGenBio is 0.4x. |
| What is the current FCF of BerGenBio? | BerGenBio's last 12 months FCF is -$14.7M. |
| What is BerGenBio's FCF margin? | BerGenBio's last 12 months FCF margin is -28571%. |
| What is the current EV/FCF multiple of BerGenBio? | Current FCF multiple of BerGenBio is 0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
